Cover Image
市場調查報告書

中國的人體疫苗產業分析

Research Report on China Human Vaccine Industry, 2011-2020

出版商 China Research and Intelligence 商品編碼 355893
出版日期 內容資訊 英文 60 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的人體疫苗產業分析 Research Report on China Human Vaccine Industry, 2011-2020
出版日期: 2016年04月06日 內容資訊: 英文 60 Pages
簡介

2015年時,中國的疫苗市場達到了210億人民幣的規模,不過,與醫藥品整體市場 (2兆人民幣以上) 相比的話,僅有1%左右的大小。中國的疫苗市場,分為公共保險對象的疫苗I市場,與自我負擔為主體的疫苗II市場,而前者由國營企業,後者由外資型企業構築獨佔地位。在中國國內存在著多數的疫苗廠商,不過,平均產業規模很小,以及在安全方面有許多課題。儘管如此,今後由於隨著對疫苗接種的理解度、認知度的上升,市場成長率上升,市場競爭也將活躍起來。

本報告提供中國的人體疫苗市場相關分析,全球整體的產業趨勢,及中國市場背景情況,整體生產體制、開發情形的轉變,各領域、疾病的市場趨勢預測,主要企業簡介,今後的市場趨勢預測等調查評估。

第1章 人體疫苗的基本概念

  • 定義
  • 疫苗的開發過程
  • 疫苗的分類
  • 疫苗接種的必要性

第2章 全球人體疫苗市場分析 (過去5年份)

  • 全球疫苗市場規模、結構
    • 疫苗的全球市場的規模
    • 疫苗接種對象者的人數
    • 全球疫苗市場結構
  • 兒童疫苗
    • 主要的品種
    • 兒童疫苗的市場規模
  • 成人疫苗
    • 主要的品種
    • 成人疫苗的市場規模

第3章 中國的人體疫苗市場發展環境

  • 經濟環境
  • 政策環境
    • 中國的疫苗接種產業的歷史
    • 疫苗接種的次序
  • 中國的疫苗產業相關的法規和標準
    • 研究開發 (R&D) 階段
    • 生產階段
    • 流通階段
    • 中國政府對疫苗產業的輔助政策
  • 中國的人體疫苗產業的問題點分析

第4章 中國的人體疫苗市場分析 (過去5年份)

  • 中國的疫苗的分類
  • 中國的疫苗市場規模
    • 概要
    • 中國的疫苗市場結構
  • 如果中國的疫苗的分類:政府的法規、標準基於
    • 疫苗I市場
    • 疫苗II市場
  • 中國國內的主要疫苗的市場分析
    • 無菌化牛型結核菌疫苗
    • 小兒麻痺疫苗
    • 麻疹、腮腺炎、德國麻疹疫苗
    • 白喉/破傷風 (DTP/DTaP) 疫苗
    • 腦炎疫苗
    • 腦膜炎疫苗
    • 人類用狂犬病(恐水症)疫苗
    • B型流感、嗜血桿菌共軛疫苗
    • 流感疫苗
    • 水痘疫苗
    • A型肝炎疫苗
    • 肺炎球菌疫苗
    • B型肝炎疫苗

第5章 中國的人體疫苗的主要製造商

  • China National Biotec Group
    • 概要
    • Beijing Tiantan Biological Products Co., Ltd.
    • 集團內的子公司
  • Hualan Biological Engineering Co., Ltd.
  • Yunnan Walvax Biotechnology Co., Ltd.
  • Dalian Hissen Biological Pharmaceutical Co., Ltd.
  • Changchun High-Tech Industry Co., Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • Neptunus Interlong Bio-Technique Co., Ltd.
  • Liaoning Chengda Biotechnology Co., Ltd.
  • ChongQing ZhiFei Biological Products Co., Ltd.

第6章 中國的疫苗產業的未來展望 (今後5年份)

  • 供需趨勢的預測
    • 生產量的預測
    • 市場規模的預測
  • 發展趨勢的預測
    • 技術趨勢
    • 市場趨勢
    • 競爭趨勢

圖表一覽

目錄
Product Code: 1604335

Currently vaccination is one of the most effective approaches to prevent the spread of infectious diseases as well as one of the most cost-effective health intervention measures. Vaccination is helpful to trim down large amount of treatment expense.

The research object of the report is human vaccine apart from animal vaccine. Five pharmaceutical giants, MSD, Sanofi, Glaxo SmithKline, Pfizer and Novartis, take up significant share of the global market, with sales volume of over 80% globally. Yet in terms of vaccine output, these five giants totally produce less than 20% of the global output, meaning most of the vaccines are produced by manufacturers in the developing world.

There are more than 30 vaccine manufacturing companies in China so far. They are capable of producing over 40 varieties of vaccines to prevent more than 20 infectious diseases. Compared with the international market, vaccine manufacturing companies in China have a larger total number yet a smaller individual scale.

In China, it is used to classifying vaccines into two catalogues: Vaccine I and Vaccine II. Vaccine I refers to those free vaccines provided by the government for the public, including vaccines against major epidemic diseases such as hepatitis B, epidemic meningitis and tetanus. Vaccines in this category are all priced by the government and purchased through bidding. Vaccine II mainly covers vaccines paid by citizens themselves. For Vaccine II, pricing falls into the hand of companies, thus offering a higher profit margin and yet forming a more fiercely competitive market. Some of the commonly used vaccines in the Vaccine II catalogue include Pneumonia Vaccine, Varicella Vaccine, Type B Haemophilus Influenzae Conjugate Vaccine, Influenza Vaccine and Rabies Vaccine. In China, Vaccine I market is dominated by state-owned enterprises. Foreign and private enterprises gain certain advantages in the Vaccine II market.

In 2015, vaccine market size in China had a value of about CNY 21 billion. During the corresponding period, however, the whole pharmaceutical market in China reached a scale of over CNY 2,000 billion. Sales of vaccine industry took up only about 1% of the whole pharmaceutical industry, much lower than the average 3% of the global market. Therefore, China's vaccine market still has much room for growth. China is a country with the largest population in the world. Every year newly born babies exceed 10 million yet meanwhile aging population is witnessing a trend of rise. As the economy advances, movement of population in China is frequent, which objectively adds to the wider and faster spread of diseases globally. Outbreaks of new epidemic diseases (such as Avian Influenza, Type A H1N1 Influenza) are more frequent.

Thanks to the technology accumulation over the years, some of China's private enterprises have gained significant breakthroughs in both the technological field and the market of Vaccine II. However, as the majority of them produce their products through copy and imitation, they are in lack of strength in core technology, manufacturing technique, innovation and competence.

In China, as some problems still remain in the supervision and regulation in human vaccine industry, related accidents pop up constantly. This makes some Chinese residents tend to choose imported vaccines. The huge potential of China's human vaccine industry attracts international giants in vaccine industry to speed up their entry to Chinese market. In 2009 Novartis offered to purchase 85% shares of Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. at USD 125 million. Such a bid was approved in March 2011. In June 2011, Glaxo SmithKline bought 51% shares of Neptunus Interlong held by Neptunus Pharmaceutical at GBP 24 million and set up a joint-venture subsidiary. In September 2011, Glaxo SmithKline signed with three new partners which were Sinopharm Group Co., Ltd., Shanghai Zuellig Pharmaceutical Co., Ltd. and Beijing Keyuan Xinhai Pharmaceutical Co., Ltd. The three distributors were respectively responsible for the distribution business in Northern, Central and Southern China. Through their cold chain logistics systems around the nation, they can provide services for clients in different parts of China.

It is estimated that China's vaccine market will still grow at a fast speed in the next few years. However as market competition is getting more intensified, some of the incompetent companies will end up in bankruptcy or be acquired and restructured. Market concentration rate will constantly go up.

Currently as vaccination rate in China is relatively low, growth in the industry in the future will be large. As China's economy develops further, residents' health awareness and paying capacity will continue to be improved, which will offer greater opportunities and market for the vaccine industry.

Through this report, readers can acquire the following information or even more:

  • Status of China Vaccine Industry
  • Government Policy of China Vaccine Industry
  • Competition Status of China Vaccine Market
  • Segmentation of China Vaccine Market
  • Major Vaccine Manufacturers in China
  • Development Trend of Vaccine Market

The following enterprises and people are proposed to purchase this report:

  • Vaccine Manufacturers
  • Medical and Anti-epidemic Institutions
  • Research Institutions/Investors Concerned about Vaccine Industry

Table of Contents

1. Basic Concept of Human Vaccine

  • 1.1. Definition
  • 1.2. Development Course of Vaccines
  • 1.3. Classification of Vaccines
  • 1.4. Necessity of Vaccination

2. Analysis on the Global Human Vaccine Market, 2011-2015

  • 2.1. Scale and Structure of Global Vaccine Market
    • 2.1.1. Scale of Global Vaccine Market
    • 2.1.2. People Appropriate for Vaccination
    • 2.1.3. Structure of Global Vaccine Market
  • 2.2. Vaccines for Children
    • 2.2.1. Major Varieties
    • 2.2.2. Market Scale of Vaccines for Children
  • 2.3. Adult Vaccines
    • 2.3.1. Major Varieties
    • 2.3.2. Market Scale of Adult Vaccines

3. Development Environment of China Human Vaccine Industry, 2011-2016

  • 3.1. Economic Environment
  • 3.2. Policy Environment
    • 3.2.1. China's Immunization Program History
    • 3.2.2. Procedure of Immunization Program
  • 3.3. Relevant Legislation and Criterion of China Vaccine Industry
    • 3.3.1. Research and Registration Stage
    • 3.3.2. Production Stage
    • 3.2.3. Circulation Stage
    • 3.3.4. Supporting Policies of Chinese Government to Vaccine Industry
  • 3.5. Analysis on Problems in China Human Vaccine Industry

4. Analysis on the China Human Vaccine Market, 2011-2015

  • 4.1. Classification of Chinese Vaccines
  • 4.2. Scale of China Vaccine Market
    • 4.2.1. Overview
    • 4.2.2. Structure of China Vaccine Market
  • 4.3. Classification of Chinese Vaccines According to Government Regulation Degrees
    • 4.3.1. Vaccine I Market
    • 4.3.2. Vaccine II Market
  • 4.4. Market Analysis on Major Vaccines in China
    • 4.4.1. Bacillus Chalmette-Guerin
    • 4.4.2. Poliomyelitis Vaccine
    • 4.4.3. Measles-Mumps-Rubella Vaccine
    • 4.4.4. Diphtheria and Tetanus (DTP or DTaP) Vaccine
    • 4.4.5. Encephalitis Vaccine
    • 4.4.6. Meningococcus Vaccine
    • 4.4.7. Human Rabies Vaccine
    • 4.4.8. Type B Haemophilus Influenzae Conjugate Vaccine
    • 4.4.9. Influenza Vaccine
    • 4.4.10. Varicella Vaccine
    • 4.4.11. Hepatitis A Vaccine
    • 4.4.12. Pneumococcus Vaccine
    • 4.4.13. Hepatitis B Vaccine

5. China's Major Vaccine Manufacturers, 2011-2015

  • 5.1. China National Biotec Group
    • 5.1.1. Overview
    • 5.1.2. Beijing Tiantan Biological Products Co., Ltd.
    • 5.1.3. Subordinate Institutions of Biological Products of China National Biotec Group
  • 5.2. Hualan Biological Engineering Co., Ltd.
  • 5.3. Yunnan Walvax Biotechnology Co., Ltd.
  • 5.4. Dalian Hissen Biological Pharmaceutical Co., Ltd.
  • 5.5. Changchun High-Tech Industry Co., Ltd.
  • 5.6. Shenzhen Kangtai Biological Products Co., Ltd.
  • 5.7. Neptunus Interlong Bio-Technique Co., Ltd.
  • 5.8. Liaoning Chengda Biotechnology Co., Ltd.
  • 5.9. ChongQing ZhiFei Biological Products Co., Ltd.

6. Prospect of China Vaccine Industry, 2016-2020

  • 6.1. Prediction on Supply and Demand
    • 6.1.1. Prediction on Production
    • 6.1.2. Prediction on Market Scale
  • 6.2. Prediction on Development Trend
    • 6.2.1. Technology Trend
    • 6.2.2. Market Trend
    • 6.2.3. Competition Trend

Selected Charts

  • Chart Introduction on Basic Ingredients of Vaccine
  • Chart Classification of Human Vaccines
  • Chart Comparison Between Traditional and New Vaccines
  • Chart Scale of the Global Vaccine Market, 2005-2015
  • Chart Introduction on Global Major Vaccines
  • Chart Major Varieties of Global Pneumonia Vaccine
  • Chart Major Hepatitis Vaccine in Global Market
  • Chart World's Major Infectious Diseases Since the 21st Century
  • Chart Market Scale of China Vaccine Industry, 2011-2015
  • Chart Lot Release Volume of BCG Vaccine in China, 2011-2015
  • Chart Market Scale of China's MMR Vaccine, 2011-2015
  • Chart Lot Release Volume of Human Rabies Vaccine in China, 2011-2015
  • Chart Lot Release Volume of Influenza Vaccine in China, 2011-2015
  • Chart Prediction on Market Scale of China Vaccine Industry, 2016-2020
  • Chart Immunization Program Procedure for Chinese Children
  • Chart Circulation of China's Vaccines
  • Chart Prediction on Scale of China Vaccine Market, 2016-2020
Back to Top